# A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Source: https://onco.cc/trials/nct04980222/  
OnCo record `nct04980222` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone and Rituximab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT04980222 by Hoffmann-La Roche, with 46 participants enrolled, started 2022-03-22 and due to reach its primary completion in 2024-09-24. Interventions recorded: Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone and Rituximab. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04980222
- Phase: 2
- Setting: A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- Sponsor: Hoffmann-La Roche
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT04980222: https://clinicaltrials.gov/study/NCT04980222

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Prednisone](https://onco.cc/drugs/prednisone/), [Rituximab](https://onco.cc/drugs/rituximab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/), [Vincristine](https://onco.cc/drugs/vincristine/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct04980222.json